Frankfurt - Delayed Quote EUR

HBM Holdings Limited (6XY.F)

0.4700

-0.0350

(-6.93%)

At close: 3:29:01 PM GMT+1

February 2025 Undervalued Small Caps With Insider Action Across Regions

In February 2025, the global markets are navigating a complex landscape marked by fluctuating economic indicators and geopolitical tensions. The S&P 600 for small-cap stocks has faced volatility due to AI competition fears and tariff risks, reflecting broader market sentiment that could impact small-cap companies. In this environment, identifying promising small-cap stocks often involves looking at those with strong fundamentals and potential resilience in the face of economic uncertainty.

Simply Wall St. 8 days ago

TFBANK.ST

SYBJF

HBMHF
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic

PR Newswire 8 days ago

HBMHF
Quanzhou Huixin Micro-credit And 2 Other Promising Penny Stocks To Watch

As global markets navigate a landscape marked by inflation concerns and political uncertainties, investors are keeping a close eye on small-cap stocks, which have recently underperformed compared to their larger counterparts. For those interested in exploring smaller or newer companies, penny stocks—an investment area that remains relevant despite the term's vintage feel—can offer intriguing opportunities. By focusing on companies with solid financial foundations and potential for growth,...

Simply Wall St. 27 days ago

1577.HK

HBMHF

1854.HK
Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of its lead program and IND-enablement of bispecificsLead program is a phase 2-ready, long-acting anti-TSLP monoclonal antibody with potential to be first-to-market with dosing every 6 monthsBuilding a discovery pipeline of long-acting bispecifics harnessing validated targets and syner

GlobeNewswire last month

HBMHF

6990.HK
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, today announced that the Company and Sichuan Kelun Biotech BioPharmaceutical (HKEX: 06990, "Kelun-Biotech") have entered into a license agreement with Windward Bio AG ("Windward Bio") for HBM9378/SKB378, an anti-thymic stromal lymphopoietin (TSLP) fully human monoclonal antibody co-

PR Newswire last month

HBMHF
HBM Holdings And 2 Other Promising Penny Stocks

As global markets navigate a complex landscape of interest rate changes and economic data, investors are increasingly looking for opportunities in niche areas like penny stocks. Although the term "penny stocks" may seem outdated, it still refers to smaller or newer companies that can offer significant growth potential when backed by strong financial health. In this article, we will explore three such penny stocks that stand out for their robust balance sheets and potential for long-term success.

Simply Wall St. last month

HBMHF

D8DU.SI

0621.HK
3 Promising Penny Stocks With Market Caps Over US$70M

As global markets navigate the uncertainties surrounding the incoming Trump administration, investors are keenly observing sector shifts and policy implications. Amid these developments, penny stocks continue to capture attention for their potential to offer value and growth opportunities at accessible price points. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can present significant upside when backed by robust financials. In this article, we explore...

Simply Wall St. 2 months ago

9686.HK

SIMTF

HBMHF
Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, is pleased to announce the appointment of Dr. Raymond Zheng as Chief Business Officer (CBO). Based in the United States, Dr. Zheng will lead global business development and alliance management functions, reporting directly to Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

PR Newswire 2 months ago

HBMHF
Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the submission of an Investigational New Drug (IND) application to the Centre for Drug Evaluation of the National Medical Products Administration of China for HBM9378/SKB378, a fully human antibody targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic

PR Newswire 3 months ago

HBMHF
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the online publication of the results from its phase I clinical trial of porustobart (HBM4003), the Company's first-in-class fully human heavy chain antibody targeting CTLA-4. The trial evaluated porustobart in combination with the anti-PD-1 antibody toripalimab for the tr

PR Newswire 4 months ago

HBMHF
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced the latest clinical data on HBM1020, a first-in-class, fully human anti-B7H7/HHLA2 monoclonal antibody, in patients with advanced solid tumors as a poster presentation (Presentation Number: 1010P) at the ESMO Congress 2024. The data has also been published online as an abstract

PR Newswire 4 months ago

HBMHF
Harbour BioMed Announces 2024 Interim Results

Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2024.

PR Newswire 5 months ago

HBMHF
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced today that the Company will release the latest clinical data on its first-in-class fully human anti-B7H7/HHLA2 monoclonal antibody, HBM1020, for advanced solid tumors at the ESMO Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain.

PR Newswire 6 months ago

HBMHF
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced a positive profit alert for the six months ended June 30, 2024 (the "Reporting Period").

PR Newswire 6 months ago

HBMHF
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announces that it has resubmitted the Biologics License Application (BLA) of batoclimab (HBM9161) to the National Medical Products Administration (NMPA) of China for the treatment of generalized myasthenia gravis (gMG).

PR Newswire 7 months ago

HBMHF
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

PR Newswire 8 months ago

HBMHF
Harbour BioMed Reports Full Year 2023 Financial Results

Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, released annual financial results of full year 2023.

PR Newswire 10 months ago

HBMHF
Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), announced today that it has entered into a collaboration agreement with Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies via modulating immune systems. The collaboration aims to leverage Nona's proprietary Harbour Mice® H2L2 (two light and two heavy chain) platform to accele

PR Newswire 11 months ago

HBMHF

Performance Overview

Return	6XY.F	HANG SENG INDEX
YTD	+143.52%	+8.75%
1-Year	+215.44%	+38.53%
3-Year	-11.32%	-12.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

HBM Holdings Limited (6XY.F)

February 2025 Undervalued Small Caps With Insider Action Across Regions

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Quanzhou Huixin Micro-credit And 2 Other Promising Penny Stocks To Watch

Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

HBM Holdings And 2 Other Promising Penny Stocks

3 Promising Penny Stocks With Market Caps Over US$70M

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Harbour BioMed Announces 2024 Interim Results

Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

Harbour BioMed Reports Full Year 2023 Financial Results

Nona Biosciences Enters into Collaboration Agreement with Boostimmune in Antibody-Drug Conjugate Development

Performance Overview